Pharmaceutical Innovation & Production Edmonton Metropolitan Region Webinar July 21, 2020
Program Introductions and Presentations • Canada Trade Commissioner Service • Sameena Qureshi, The Hague, Netherlands • Michelle Gartland, Belgium and Luxembourg • Stefan Scherer, Edmonton Global • Michael Overduin, University of Alberta • Andrew MacIsaac, Applied Pharmaceutical Innovation • Greg Klak, Gilead Question & Answer • Amanpreet Bhatti, Moderator
Let us handle the introductions Laissez-nous faire les présentations Pharmaceutical Innovation & Production Opportunities in the Edmonton Region July 21, 2020
Canada's Key Strengths in the Pharmaceuticals Sector Research & Development Advantages One of the most generous R & D tax • incentives in the industrialized world A well-developed contract services • industry, including contract research organizations (CROs) & contract manufacturing organizations (CMO) Canada’s commercially oriented research network takes • innovation from lab to market ; joint investment opportunities in research allow for R&D result optimization. https://www.investcanada.ca/industries/life-sciences https://www.investcanada.ca/industries/life-sciences
Canada's Key Strengths in the Pharmaceuticals Sector A Low Cost Research and Manufacturing Base Ranks 2nd for cost-effectiveness in • the establishment and operation of pharmaceuticals facilities (Source: Competitive Alternatives Report of 2016 by KPMG). Ranks 2nd among G7 countries for • clinical trials operations , offering significant cost savings over the US, according to the same report.
Canada's Key Strengths in the Pharmaceuticals Sector Skilled Labour Pool A world-class education system , • with an extensive network of academic health institutions, research centres, 17 medical schools, and over 13,000 health researchers employed at dozens of health care organizations. The highest educated workforce in the OECD. Of those graduates, over 4.8 • million hold a degree from a STEM or health care program. In addition to ranking 4th globally for the availability of scientists and • engineers, Canada’s Global Skills Strategy allows employers to bring in highly skilled talent from abroad in as little as two weeks.
Canada's Key Strengths in the Pharmaceuticals Sector Logistics and Market Access Benefits Canada is the 10 th largest • market for pharmaceuticals sales A highly developed transport • and logistics infrastructure which, according to the World Bank, is one of the world’s best. Take advantage, thanks to CUSMA, of duty-free access to U.S . • market, the largest drugs consumption market, and to Mexico’s own growing pharmaceuticals market.
CETA: Opportunities and Benefits for the Pharmaceutical Sector v Luxembourg ratified CETA on May 6, 2020 v Guaranteed preferential access to the EU and North American markets; v Enhanced intellectual property rights provide greater protection for investments made in Canada’s pharmaceutical industry; v CETA provides a mechanism for Canada and the EU to mutually accept the results of each other’s inspections of pharmaceutical manufacturers; v Greater access to government procurement markets : CETA’s government procurement provisions cover the procurement of pharmaceutical products as well as a broad range of services that may be of interest to the pharmaceutical sector, including technical testing and analysis services. https://www.international.gc.ca/trade-commerce/trade-agreements-accords- commerciaux/agr-acc/ceta-aecg/business-entreprise/sectors-secteurs/PE-EPP.aspx?lang=eng
How Can we help you? v Assistance in developing a business case for your next investment decision. v Strategic, sector-specific market intelligence. v Path-finding for key government contacts engaged in supporting investment in Canada. v Referrals to investment support professionals and private-sector industry associations. v Facilitation of site visits to support you in the identification of a strategic location. v Information and advice on how to set up a business in Canada, taxation, regulations and government programs. Ask for a one-on-one consultation after the webinar
Trade Commissioner Service in the Netherlands and in Luxembourg Trade Commissioner Service in the Netherlands Trade Commissioner Service in Luxembourg Sameena QURESHI Michelle GARTLAND Senior Trade Commissioner Senior Trade Commissioner Embassy of Canada to the Kingdom of the Netherlands Embassy of Canada to the Grand Duchy of Luxembourg sameena.qureshi@international.gc.ca michelle.gartland@international.gc.ca T: +31-70 311 1690 T: +32 2 741 0622 Melanie TER MEULEN Fabienne DE KIMPE Trade Commissioner Investment Trade Commissioner Life Sciences melanie.termeulen@international.gc.ca fabienne.de-kimpe@international.gc.ca T+31-70 311 1692 T: +32 2 741 0621 Caroline BOLDUC Trade Commissioner Science and Technology caroline.bolduc@international.gc.ca T: +31-70 311 1653 www.tradecommissioner.gc.ca - www.investcanada.ca 10
EDMONTON METROPOLITAN REGION Stefan Scherer Trade & Investment Team
EDMONTON METROPOLITAN REGION — We Are Young, Educated, and Growing YOUNG EDUCATED GROWING The youngest 130,000+ students The fastest-growing region in communities in Canada enrolled in Canada, attracting investment, and seven universities attention, and top talent from the top community for youth and colleges around the world
EDMONTON METROPOLITAN REGION — Life Sciences and Pharmaceutical Expertise & Talent Alberta Health Services - largest integrated health system Re Research institutes • Li Ka Shing Applied Virology Institute (AVI) • Alberta Diabetes Institute (ADI) • Alberta Machine Intelligence Institute (Amii) • (NRC) Canada Nanotechnology Research Centre • Institute of Health Economics Co Commercia ializ lizatio ion a n and nd I Inno nnovatio ion • Applied Pharmaceutical Innovation (API) • TEC Edmonton Health Accelerator • Health City • BioAlberta • Genome Alberta
HEALTH & LIFE SECTORS — Life Science & Connectivity • 58% of Alberta's biotech companies and nearly 70% of Alberta’s life science companies are located in the region • 200% growth in biotech research and development spending • sector contributes nearly 7.5% to the region’s GDP • Edm Edmonton Int’l Ai Airport is the first airport in Canada to achieve certification from the Int’l Air Transport Association (IATA) for Center of Excellence for Independent Validators in Pharmaceutical Logistics ( CE CEIV P Pha harma ).
CANADA — Trade ecosystem • Preferential market access through 14 trade agreements to 51 countries • Port Alberta - an inland Port - Foreign Trade Zone • Integrated supply chain and connections by Rail, Road, Air, and Pipeline • Access to Asia 3-4 days faster through direct link from Edmonton via Port of Prince Rupert • Circumpolar air routes to Asia and Europe including 24-hour access for air transport
EDMONTON METROPOLITAN REGION
UNIVERSITY OF ALBERTA & DISCOVERY LAB Michael Overduin Professor, Dept of Biochemistry, UAlberta CAMSEED Drug Discovery Consortium Founder and co-Director, SMALP Network Founder and co-Director, DiscoveryLab Funders:
Kinome screen + hit-lead optimization yields candidates for type 2 diabetes, triple negative breast cancer and Alzheimers disease 1. Kinome screening 4. Structure-aided design of 3. hits & binding >800 kinase inhibitors modes by NMR NMR spectrum 5. Efficacious and selective leads in cell & mouse models 6. Patent, pubs (Fromont C. et al. J Med Chem, 2020) 2. CaMK1D target feasibility
Membrane proteins represent the majority of drug targets and can only be solubilized and analysed in native states using SMALP technology 1. Membrane targets 4. Patents filed, SMALP industry club formed, improved polymers, assays, drug discovery platforms 3. Membrane target including bound native lipids, post- translational modifications by methods including cryo-EM Asymmetric lipid bilayer 2. Biological material Alternative Complex III, C Sun, Nature, 2018 Open and Super Open Glycine Receptor, J Yu et al. 2020
DiscoveryLab: moving valuable discoveries from the lab into the market 1. Quarterly events for inventors modelled on Science Capital, based in EU, UK 2. Over 180 spinout, start-up pitches in Alberta since 2017 3. Over 150 business, IP and finance advisors, industry experts, investors 4. Over $115 million raised by teams who pitched in 2019 5. Aligned universities, facilities, tech transfer services
EDMONTON METROPOLITAN REGION
About API We are an industry centered not-for-profit institute focused on supporting and expanding the pharmaceutical industry in Alberta We work in a unique model focused on unlocking the potential of academic institutions to support the development and manufacture of life science products We have supported over 30 companies in the past 2 years from around the globe in all stages of drug development, from training and developing active pharmaceutical ingredient manufacturing to running bioanalytical studies to clinical trials and pk reporting
Recommend
More recommend
